MWR
DGX icon

McAdams Wright Ragen’s Quest Diagnostics DGX Stock Holding History

McAdams Wright Ragen’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-8,800
Closed -$544K – 377
2013
Q3 		$544K Sell
8,800
-40
-0.5% -$2.39K 0.04% 213
2013
Q2 		$536K Buy
+8,840
New +$527K 0.04% 210

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

McAdams Wright Ragen's DGX Position: Q4 2013 in Review

McAdams Wright Ragen sold out of Quest Diagnostics (DGX) in Q4 2013, closing a stake of 8,800 shares — an estimated $544K sold.

McAdams Wright Ragen first reported a position in DGX in Q2 2013 and held it in 2 quarters. The position peaked at $544K in Q3 2013. 455 funds tracked by Wall St. Rank hold DGX as of Q4 2013.

  • McAdams Wright Ragen reported no remaining Quest Diagnostics position as of Q4 2013 after selling out during the quarter.
  • McAdams Wright Ragen sold 8,800 Quest Diagnostics shares in Q4 2013, an estimated $544K.
  • McAdams Wright Ragen first reported a position in Quest Diagnostics in Q2 2013 and held it in 2 quarters.
  • McAdams Wright Ragen's Quest Diagnostics position peaked at $544K in Q3 2013.
  • 455 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2013.

Based on McAdams Wright Ragen's 13F filing for Q4 2013, filed 11 Feb 2014.